APRE

Aprea Therapeutics, Inc. APRE

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$1.90M total
AIGH Capital Management LLC
$814.8K0.0%
Vestal Point Capital, LP
$280.8K0.0%
SPHERA FUNDS MANAGEMENT LTD.
$216.6K0.0%
Nantahala Capital Management, LLC
$165.1K0.0%
RENAISSANCE TECHNOLOGIES LLC
$84.9K+321.5%
GEODE CAPITAL MANAGEMENT, LLC
$60.1K-37.2%
CITADEL ADVISORS LLC
$47.0KNew
BNP PARIBAS FINANCIAL MARKETS
$36.3K+13.5%
DIADEMA PARTNERS LP
$36.0KNew
VANGUARD FIDUCIARY TRUST CO
$30.8K0.0%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$28.0K+168.4%
MORGAN STANLEY
$20.7K+15.7%
VANGUARD CAPITAL MANAGEMENT LLC
$18.4K+16.6%
LPL Financial LLC
$12.9K-23.8%
HighTower Advisors, LLC
$11.1K0.0%
NORTHERN TRUST CORP
$11.0KNew
Persistent Asset Partners Ltd
$9.2KNew
XTX Topco Ltd
$8.5KNew
BlackRock, Inc.
$5.8K-15.7%
Tower Research Capital LLC (TRC)
$2.9K-30.0%
GROUP ONE TRADING, L.P.
$4630.0%
BARCLAYS PLC
$379New
OSAIC HOLDINGS, INC.
$2360.0%
WealthCollab, LLC
$1270.0%
Integrated Wealth Concepts LLC
$36New
See all 29 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/APRE

Earnings Per Share

13fpro.ai/company/APRE

Loading ratio trend…

APRE insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Aprea Therapeutics, Inc. (APRE): stock profile, AI score and financials

Aprea Therapeutics, Inc. (APRE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. APRE is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of APRE by reported 13-F value include AIGH Capital Management, Vestal Point Capital, SPHERA FUNDS MANAGEMENT LTD., based on the most recent SEC filings. APRE trades on the Nasdaq exchange and files with the SEC under CIK 1781983. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APRE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aprea Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1781983 →